JP7805946B2 - GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体 - Google Patents

GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体

Info

Publication number
JP7805946B2
JP7805946B2 JP2022557102A JP2022557102A JP7805946B2 JP 7805946 B2 JP7805946 B2 JP 7805946B2 JP 2022557102 A JP2022557102 A JP 2022557102A JP 2022557102 A JP2022557102 A JP 2022557102A JP 7805946 B2 JP7805946 B2 JP 7805946B2
Authority
JP
Japan
Prior art keywords
methyl
group
methoxy
tetrahydro
methylpyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022557102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520647A (ja
JP2023520647A5 (cg-RX-API-DMAC7.html
Inventor
ザボー、ジェルジュ
ポトル、アッティラ
バーゴー、イシュトバーン
ジェルジュ、イシュトバーン トゥーローシュ
エーリアーシュ、オリヴィエ
ラースロー カプシュ、ガーボル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2023520647A publication Critical patent/JP2023520647A/ja
Publication of JP2023520647A5 publication Critical patent/JP2023520647A5/ja
Application granted granted Critical
Publication of JP7805946B2 publication Critical patent/JP7805946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022557102A 2020-03-26 2021-03-25 GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体 Active JP7805946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP2000113 2020-03-26
HUP2000113 2020-03-26
PCT/IB2021/052486 WO2021191838A1 (en) 2020-03-26 2021-03-25 NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (3)

Publication Number Publication Date
JP2023520647A JP2023520647A (ja) 2023-05-18
JP2023520647A5 JP2023520647A5 (cg-RX-API-DMAC7.html) 2024-03-11
JP7805946B2 true JP7805946B2 (ja) 2026-01-26

Family

ID=89666363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557102A Active JP7805946B2 (ja) 2020-03-26 2021-03-25 GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体

Country Status (22)

Country Link
US (1) US12637455B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126859A1 (cg-RX-API-DMAC7.html)
JP (1) JP7805946B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220160061A (cg-RX-API-DMAC7.html)
CN (1) CN115348962A (cg-RX-API-DMAC7.html)
AR (1) AR121666A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021244926B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019128A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171441A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002568A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014877A2 (cg-RX-API-DMAC7.html)
CU (1) CU24714B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP22082367A (cg-RX-API-DMAC7.html)
GE (2) GEP20257761B (cg-RX-API-DMAC7.html)
IL (1) IL296716A (cg-RX-API-DMAC7.html)
JO (1) JOP20220219A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011933A (cg-RX-API-DMAC7.html)
PE (1) PE20221836A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552340A1 (cg-RX-API-DMAC7.html)
TW (1) TWI901650B (cg-RX-API-DMAC7.html)
WO (1) WO2021191838A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211414B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
HU231691B1 (hu) * 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116854685A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-稠环类衍生物、药物组合物和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511533A (ja) 2005-10-11 2009-03-19 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール誘導体
JP2009514924A (ja) 2005-11-09 2009-04-09 エフ.ホフマン−ラ ロシュ アーゲー 3−アリール−イソオキサゾール−4−カルボニル−ベンゾフラン誘導体
JP2013543852A (ja) 2010-11-09 2013-12-09 エフ.ホフマン−ラ ロシュ アーゲー トリアゾール誘導体及びその神経障害に対する使用
JP2015521642A (ja) 2012-06-26 2015-07-30 サニオナ・エイピイエス フェニルトリアゾール誘導体及びgabaa受受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2018104419A1 (en) 2016-12-08 2018-06-14 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237793B (it) 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
FR2728900B1 (fr) * 1994-12-29 1997-01-31 Synthelabo Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique
WO1998050385A1 (en) 1997-05-08 1998-11-12 Merck Sharp & Dohme Limited SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB0017518D0 (en) 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7595395B2 (en) 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
ES2340221T3 (es) 2006-05-24 2010-05-31 Eli Lilly And Company Compuestos y procedimientos para modular fxr.
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
BRPI0812521A2 (pt) 2007-06-13 2015-06-23 Glaxosmithkline Llc Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
US7618973B2 (en) 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
JP5301557B2 (ja) 2007-12-04 2013-09-25 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
KR101354416B1 (ko) 2009-05-07 2014-02-19 에프. 호프만-라 로슈 아게 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
CN103189062B (zh) 2010-11-05 2016-03-23 霍夫曼-拉罗奇有限公司 活性药物化合物用于治疗中枢神经系统病症的用途
RU2582337C2 (ru) 2010-11-09 2016-04-27 Ф.Хоффманн-Ля Рош Аг Производные триазола в качестве лигандов рецепторов гамк
KR20140014205A (ko) * 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 키나제 억제제 및 그의 사용 방법
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN102924452B (zh) * 2012-11-16 2015-01-21 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US9296747B1 (en) * 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
CA2990564A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic amide derivative
JP2018525429A (ja) 2015-08-28 2018-09-06 アッヴィ・インコーポレイテッド S1p調節剤としての縮合複素環化合物
CN108602811B (zh) 2016-02-01 2021-11-16 轩竹生物科技有限公司 Fxr受体激动剂
EP4129297A1 (en) 2016-03-18 2023-02-08 UWM Research Foundation, Inc. Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists
US20200268728A1 (en) * 2016-12-20 2020-08-27 Sumitomo Dainippon Pharma Co., Ltd. Drug targeting cancer stem cell
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
AU2019286312B2 (en) 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
BR102019014802A2 (pt) * 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511533A (ja) 2005-10-11 2009-03-19 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール誘導体
JP2009514924A (ja) 2005-11-09 2009-04-09 エフ.ホフマン−ラ ロシュ アーゲー 3−アリール−イソオキサゾール−4−カルボニル−ベンゾフラン誘導体
JP2013543852A (ja) 2010-11-09 2013-12-09 エフ.ホフマン−ラ ロシュ アーゲー トリアゾール誘導体及びその神経障害に対する使用
JP2015521642A (ja) 2012-06-26 2015-07-30 サニオナ・エイピイエス フェニルトリアゾール誘導体及びgabaa受受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2018104419A1 (en) 2016-12-08 2018-06-14 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE STN REGISTRY file, [online], RN 2331259-96-0, Entered STN: 12 Jun 2019, [retrieved on 23 Dec. 2024]
DATABASE STN REGISTRY file, [online], RN 2411227-75-1, Entered STN: 05 Mar 2020, [retrieved on 23 Dec. 2024]
DATABASE STN REGISTRY file,[online], RN 1936066-47-5, Entered STN: 21 Jun 2016, [retrieved on 23 Dec. 2024]
DATABASE STN REGISTRY file,[online], RN 2094374-04-4, Entered STN: 02 May 2017, [retrieved on 23 Dec. 2024]
DATABASE STN REGISTRY file,[online], RN 2094711-87-0, Entered STN: 02 May 2017, [retrieved on 23 Dec. 2024]

Also Published As

Publication number Publication date
CO2022014877A2 (es) 2022-10-31
GEP20257761B (en) 2025-04-10
BR112022019128A2 (pt) 2022-11-08
IL296716A (en) 2022-11-01
MX2022011933A (es) 2022-10-20
JOP20220219A1 (ar) 2022-09-13
PH12022552340A1 (en) 2023-11-29
KR20220160061A (ko) 2022-12-05
CA3171441A1 (en) 2021-09-30
JP2023520647A (ja) 2023-05-18
WO2021191838A1 (en) 2021-09-30
EP4126859A1 (en) 2023-02-08
PE20221836A1 (es) 2022-11-29
AU2021244926B2 (en) 2026-06-25
US20240067637A1 (en) 2024-02-29
TWI901650B (zh) 2025-10-21
CU20220058A7 (es) 2023-05-11
AR121666A1 (es) 2022-06-29
ZA202211414B (en) 2023-06-28
CU24714B1 (es) 2024-07-10
US12637455B2 (en) 2026-05-26
AU2021244926A1 (en) 2022-11-03
CL2022002568A1 (es) 2023-03-24
TW202202495A (zh) 2022-01-16
GEAP202416066A (en) 2024-12-10
CN115348962A (zh) 2022-11-15
ECSP22082367A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
EP4126858B1 (en) Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
EP3856342B1 (en) Bicyclic derivatives as gabaa a5 receptor modulators
TWI901650B (zh) 啶及吡啶并〔3,4-c〕嗒衍生物
EA006234B1 (ru) Производные имидазопиримидина в качестве лигандов для гамк рецепторов
JP5117192B2 (ja) 置換ベンゾジアゼピン誘導体
JP2024536039A (ja) GABAA α5受容体モジュレーターとしての二環式アミン誘導体
EP3137469A1 (en) Heterocyclic compounds and their use as dopamine d1 ligands
EA049237B1 (ru) ПРОИЗВОДНЫЕ НАФТИРИДИНА И ПИРИДО[3,4-c]ПИРИДАЗИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 5 РЕЦЕПТОРОВ GABAA
EA052124B1 (ru) БИЦИКЛИЧЕСКИЕ АМИНОПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ α5 РЕЦЕПТОРОВ GABAA
EA045543B1 (ru) БИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA
EA049500B1 (ru) ПРОИЗВОДНЫЕ 1,3-ДИГИДРО-2Н-ПИРРОЛО[3,4-с]ПИРИДИНА КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250923

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260114

R150 Certificate of patent or registration of utility model

Ref document number: 7805946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150